Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.62
+0.04 (1.55%)
Market open: Aug 12, 2026, 1:37 PM EDT
2.62
+0.04 (1.55%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder & Executive Chairman |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Dr. Zhong Zhong Ph.D. |
| Date | Type | Document |
|---|---|---|
| 2026-07-08 | 8-K | ovid-20260707.htm |
| 2026-06-11 | 8-K | ovid-20260611.htm |
| 2026-06-03 | 8-K | ovid-20260602.htm |
| 2026-05-12 | 8-K | ovid-20260512.htm |
| 2026-05-12 | 10-Q | ovid-20260331.htm |
| 2026-04-27 | DEFA14A | ovid-20260427.htm |
| 2026-04-27 | DEF 14A | ovid-20260427.htm |
| 2026-04-27 | ARS | a2025form10kforannualreport.pdf |
| 2026-04-23 | CORRESP | filename1.htm |
| 2026-04-21 | S-3 | d108102ds3.htm |
| Chief Scientific Officer |
| Mr. Charles Ross Carter M.B.A., M.S. | CFO, Principal Financial Officer, Principal Accounting Officer & Secretary |
| Mr. Jeffrey A. Rona | Advisor |
| Ms. Margaret Alexander | CEO, President & Director |
| Ms. Victoria Fort | Chief Strategy Officer |